{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:48:55Z","timestamp":1793821735519,"version":"4.6.1"},"update-to":[{"DOI":"10.1002\/14651858.cd008521.pub5","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000}}],"reference-count":426,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008521.pub6","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T17:10:44Z","timestamp":1637169044000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Vaccines for preventing rotavirus diarrhoea: vaccines in use"],"prefix":"10.1002","volume":"2021","author":[{"given":"Hanna","family":"Bergman","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Henschke","sequence":"additional","affiliation":[{"name":"Cochrane Response; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hungerford","sequence":"additional","affiliation":[{"name":"Institute of Infection, Veterinary and Ecological Sciences; University of Liverpool; Liverpool UK"},{"name":"NIHR Health Protection Research Unit in Gastrointestinal Infections; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femi","family":"Pitan","sequence":"additional","affiliation":[{"name":"Chevron Corporation; Lagos Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duduzile","family":"Ndwandwe","sequence":"additional","affiliation":[{"name":"Cochrane South Africa; South African Medical Research Council\u00a0; Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Cunliffe","sequence":"additional","affiliation":[{"name":"Institute of Infection, Veterinary and Ecological Sciences; University of Liverpool; Liverpool UK"},{"name":"NIHR Health Protection Research Unit in Gastrointestinal Infections; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Soares-Weiser","sequence":"additional","affiliation":[{"name":"Editorial & Methods Department; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD008521.pub6-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.vaccine.2011.01.018","article-title":"Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007","volume":"29","author":"Anh","year":"2011","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0002|cit2","unstructured":"A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines www.gsk-studyregister.com\/study\/3204"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0003|cit3","unstructured":"Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants clinicaltrials.gov\/show\/NCT00432380"},{"issue":"11","key":"10.1002\/14651858.CD008521.pub6-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.vaccine.2011.01.018","article-title":"Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007","volume":"29","author":"Anh","year":"2011","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Anh DD Thiem VD Hutagalung Y Bock HL Suryakiran P Delem A Immunogenicity, reactogenicity and safety of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix\u2122) oral suspension (liquid formulation) in Vietnamese Infants 13th International Congress on Infectious Diseases Abstracts, Poster Presentations; June 19-22, 2008; Kuala Lumpur, Malaysia 2008","DOI":"10.1016\/j.ijid.2008.05.366"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0006|cit6","unstructured":"A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam www.gsk-studyregister.com\/study\/3012"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0007|cit7","unstructured":"A placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Bio oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Vietnam clinicaltrials.gov\/show\/NCT00345956"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0264-410X(97)00210-7","article-title":"Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12","volume":"16","author":"Bernstein","year":"1998","journal-title":"Vaccine"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1086\/344732","article-title":"Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants","volume":"186","author":"Bernstein","year":"2002","journal-title":"Journal of Infectious Diseases"},{"issue":"9175","key":"10.1002\/14651858.CD008521.pub6-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0140-6736(98)12106-2","article-title":"Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial","volume":"354","author":"Bernstein","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1093\/cid\/ciw346","article-title":"Delayed dosing of oral rotavirus vaccine demonstrates decreased risk of rotavirus gastroenteritis associated with serum zinc: a randomized controlled trial","volume":"63","author":"Colgate","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"744","DOI":"10.4269\/ajtmh.14-0518","article-title":"The \"Performance of Rotavirus and Oral Polio Vaccines in Developing Countries\" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems","volume":"92","author":"Kirkpatrick","year":"2015","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"9","key":"10.1002\/14651858.CD008521.pub6-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/infdis\/jiy054","article-title":"Histo-blood group antigen phenotype determines susceptibility to genotype-specific rotavirus infections and impacts measures of rotavirus vaccine efficacy","volume":"217","author":"Lee","year":"2018","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0014|cit14","first-page":"226","article-title":"Lewis antigen and secretor status mediate susceptibility to p-genotype specific rotavirus infections but do not affect rotavirus vaccine performance among infants in Bangladesh","volume":"97","author":"Lee","year":"2017","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0015|cit15","unstructured":"Exploration of the biologic basis for underperformance of oral polio and rotavirus vaccines in Bangladesh PROVIDE clinicaltrials.gov\/show\/NCT01375647"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/infdis\/jix668","article-title":"Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study","volume":"217","author":"Rogawski","year":"2018","journal-title":"Journal of Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.inf.0000164763.55558.71","article-title":"Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine","volume":"24","author":"Dennehy","year":"2005","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"18","key":"10.1002\/14651858.CD008521.pub6-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1016\/j.vaccine.2005.07.030","article-title":"A short report on the highlights of world-wide development of RIX4414: a North American experience comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine (RIX4414) in infants in the United States and Canada","volume":"24","author":"Dennehy","year":"2006","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0019|cit19","unstructured":"A phase II, double-blind, randomized, placebo-controlled study of two doses of GlaxoSmithKline Biologicals\u2019 live attenuated human rotavirus (HRV) vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with human rotavirus www.gsk-studyregister.com\/study\/6783"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0020|cit20","unstructured":"Study of two doses of GSK Biologicals' live attenuated HRV vaccine (two different formulations) in healthy infants clinicaltrials.gov\/ct2\/show\/NCT00729001"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0021|cit21","unstructured":"A phase II, double-blind, randomized, placebo-controlled clinical study to assess the immunogenicity and reactogenicity of three doses of a modified vaccine formulation versus GlaxoSmithKline (GSK) Biologicals\u2019 live attenuated human rotavirus (HRV) vaccine when orally administered to healthy infants at 2, 4 and 6 months of age www.gsk-studyregister.com\/study\/6789"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0022|cit22","unstructured":"A phase III, randomized, double-blind and placebo-controlled study to assess the clinical consistency of three production lots of GSK Biologicals\u2019 HRV vaccine in terms of immunogenicity and safety when given to healthy infants at 2 and 4 months of age www.gsk-studyregister.com\/study\/6794"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0023|cit23","unstructured":"L\u00f3pez P Galan Herrera JF Cervantes Y Costa Clemens SA Aguirre F Yarzabal JP Three consecutive production lots of the human monovalent RIX4414 G1P(8) rotavirus vaccine, Rotarix\u2122 induce a consistent immune response in Latin American infants [poster] 4th World Congress of The World Society for Pediatric Infectious Diseases; 2005 September 01-04; Warsaw, Poland 2005"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0024|cit24","unstructured":"Assessment of clinical consistency of three production lots of GSK Biologicals' HRV vaccine clinicaltrials.gov\/ct2\/show\/NCT00757770"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0025|cit25","unstructured":"A phase IIIb, double-blind, randomized, placebo-controlled, multicentre study to assess the immunogenicity, safety and reactogenicity of 2 doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus www.gsk-studyregister.com\/study\/2714"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0026|cit26","unstructured":"Assess the immunogenicity, safety & reactogenicity of 2 doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants (6-12 weeks of age at first dose) previously uninfected with human rotavirus clinicaltrials.gov\/ct2\/show\/record\/NCT00134732"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0027|cit27","unstructured":"A phase II, double-blind, randomized, placebo-controlled study to compare the immunogenicity, reactogenicity and safety of 2 different formulations of GlaxoSmithKline (GSK) Biologicals\u2019 live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV www.gsk-studyregister.com\/study\/2632"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0028|cit28","unstructured":"Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants www.gsk-studyregister.com\/study\/3131"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0029|cit29","unstructured":"Kawamura N Tokoeda Y Mori S Ohshima M Okahata H Ueda D Efficacy of human rotavirus vaccine RIX4414 in Japanese infants from 2 weeks post dose 2 up to data lock point 28th Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2010 May 04-08; Nice, France 2010"},{"issue":"37","key":"10.1002\/14651858.CD008521.pub6-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1016\/j.vaccine.2011.05.017","article-title":"Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life","volume":"29","author":"Kawamura","year":"2011","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0031|cit31","unstructured":"Efficacy, safety, reactogenicity and immunogenicity study of the lyophilised formulation of Rotarix vaccine in healthy Japanese infants clinicaltrials.gov\/show\/NCT00480324"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0032|cit32","unstructured":"A phase IIIb, partially blind, randomized, placebo-controlled study to asses the effect on immunogenicity of administration of vaccine without buffering agent and to assess heat stability in terms of immunogenicity, reactogenicity and safety of GlaxoSmithKline Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 month schedule, in healthy infants previously uninfected with human rotavirus www.gsk-studyregister.com\/study\/2713"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0033|cit33","unstructured":"Kerdpanich A Chokephaibulkit K Watanaveeradej V Vanprapar N Hutagalung Y Han HH Exposure to elevated temperature of 37\u00b0C for 7 days does not affect immunogenicity and reactogenicity of RIX4414 [poster] dsRNA Virus Meeting; 2006 October 21-26; Cape Town, South Africa 2006"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4161\/hv.7.1.13412","article-title":"Immunogenicity of a human rotavirus vaccine (RIX4414) after storage at 37 degrees C for seven days","volume":"7","author":"Kerdpanich","year":"2011","journal-title":"Human Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.4161\/hv.6.3.10428","article-title":"Immunogenicity of a live-attenuated human rotavirus RIX4414 vaccine with or without buffering agent","volume":"6","author":"Kerdpanich","year":"2010","journal-title":"Human Vaccines"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0036|cit36","unstructured":"Assess the effect on immunogenicity of administration of vaccine without buffering agent & assess heat stability in terms of immunogenicity, reactogenicity & safety of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine following a 0, 2 m schedule, in healthy infants previously uninfected with human rotavirus clinicaltrials.gov\/show\/NCT00169455"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0037|cit37","unstructured":"Immunogenicity, reactogenicity and safety study to evaluate two doses of the lyophilised formulation of the human rotavirus (HRV) vaccine when administered to healthy Korean infants previously uninfected with HRV www.gsk-studyregister.com\/study\/3589"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"806","DOI":"10.4161\/hv.19853","article-title":"Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: a randomized, double-blind, placebo-controlled, phase IV study","volume":"8","author":"Kim","year":"2012","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0039|cit39","unstructured":"Study to evaluate immunogenicity, reactogenicity and safety of Rotarix\u2122 vaccine in Korean infants clinicaltrials.gov\/ct2\/show\/NCT00969228"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0040|cit40","unstructured":"Reactogenicity and safety of a single dose of GlaxoSmithKline (GSK) Biologicals' human rotavirus (HRV) vaccine (444563) in healthy children www.gsk-studyregister.com\/study\/3957"},{"issue":"8","key":"10.1002\/14651858.CD008521.pub6-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.4161\/hv.25076","article-title":"Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled phase I studies","volume":"9","author":"Li","year":"2013","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0042|cit42","unstructured":"Study to evaluate the safety of Rotarix in Chinese children clinicaltrials.gov\/ct2\/show\/NCT01086436"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0043|cit43","unstructured":"Reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated liquid human rotavirus (HRV) vaccine 444563, in healthy infants www.gsk-studyregister.com\/study\/3947"},{"issue":"8","key":"10.1002\/14651858.CD008521.pub6-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.4161\/hv.25076","article-title":"Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled phase I studies","volume":"9","author":"Li","year":"2013","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0045|cit45","unstructured":"Study to assess the safety of GSK Biologicals' liquid human rotavirus vaccine in healthy infants clinicaltrials.gov\/ct2\/show\/NCT01107587"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0046|cit46","unstructured":"Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid Human Rotavirus (HRV) vaccine (444563), in healthy infants www.gsk-studyregister.com\/study\/4036"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4161\/hv.26319","article-title":"Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: a randomized, placebo-controlled trial in China","volume":"10","author":"Li","year":"2014","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/21645515.2015.1085143","article-title":"Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants","volume":"12","author":"Li","year":"2016","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0049|cit49","unstructured":"Efficacy, immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated liquid human rotavirus (HRV) vaccine (444563), in healthy infants clinicaltrials.gov\/show\/NCT01171963"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"A36","DOI":"10.1016\/j.vaccine.2011.09.120","article-title":"Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial","volume":"30","author":"Cunliffe","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMoa0904797","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"362","author":"Madhi","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"A44","DOI":"10.1016\/j.vaccine.2011.08.080","article-title":"Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Madhi","year":"2012","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0053|cit53","unstructured":"Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants clinicaltrials.gov\/show\/NCT00241644"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0054|cit54","unstructured":"Multi-center study to assess efficacy, safety & immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants clinicaltrials.gov\/show\/NCT00598468"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1471-2334-12-213","article-title":"Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial","volume":"12","author":"Steele","year":"2012","journal-title":"BMC Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"A36","DOI":"10.1016\/j.vaccine.2011.09.120","article-title":"Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial","volume":"30","author":"Cunliffe","year":"2012","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMoa0904797","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"362","author":"Madhi","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0058|cit58","unstructured":"Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants clinicaltrials.gov\/show\/NCT00241644"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0059|cit59","unstructured":"Multi-center study to assess efficacy, safety & immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants clinicaltrials.gov\/show\/NCT00598468"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1471-2334-12-213","article-title":"Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial","volume":"12","author":"Steele","year":"2012","journal-title":"BMC Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJMoa0904797","article-title":"Effect of human rotavirus vaccine on severe diarrhea in African infants","volume":"362","author":"Madhi","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"A44","DOI":"10.1016\/j.vaccine.2011.08.080","article-title":"Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus seasons: a randomized, double-blind, placebo-controlled trial","volume":"30","author":"Madhi","year":"2012","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0063|cit63","unstructured":"Multi-center study to assess the efficacy, safety and immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants clinicaltrials.gov\/show\/NCT00241644"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0064|cit64","unstructured":"Multi-center study to assess efficacy, safety & immunogenicity of 2 or 3 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations in healthy infants clinicaltrials.gov\/show\/NCT00598468"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1471-2334-12-213","article-title":"Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial","volume":"12","author":"Steele","year":"2012","journal-title":"BMC Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0066|cit66","unstructured":"A phase IIIb, randomised, multicentre double-blind, placebo-controlled study of the immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine (RIX4414) as primary dosing in healthy infants in India of approximately 8 weeks of age at the first dose www.gsk-studyregister.com\/study\/2723"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4161\/hv.5.6.8176","article-title":"Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants","volume":"5","author":"Narang","year":"2009","journal-title":"Human Vaccines"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0068|cit68","unstructured":"A multicenter study of the immunogenicity & safety of 2 doses of GSK Biologicals\u2019 oral live attenuated human rotavirus vaccine (RIX4414) as primary dosing of healthy infants in India aged approximately 8 wks at the time of the first dose clinicaltrials.gov\/ct2\/show\/record\/NCT00289172"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0069|cit69","unstructured":"A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals\u2019 Tritanrix\u2122-HepB and GSK Biologicals Kft\u2019s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory\u2019s (CSL\u2019s) DTPw (Triple Antigen\u2122) and GSK Biologicals\u2019 HBV (Engerix\u2122-B), when co-administered with GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4\u00bd and 6 months of age, after a birth dose of hepatitis B vaccine www.gsk-studyregister.com\/study\/2753"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0070|cit70","unstructured":"Assess immunogenicity & reactogenicity of 2 formulations of GSK's DTPw-HBV vaccines vs concomitant admn of CSL's DTPw & GSK's HBV vaccine, co-admnd with GSK's rotavirus vaccine, to infants at 3, 4\u00bd & 6 mths, after birth dose of HBV vaccine clinicaltrials.gov\/show\/NCT00158756"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0071|cit71","doi-asserted-by":"crossref","unstructured":"Tatochenko VK Romanenko VV Kharit SM Smolenov I LeFevre I De Clercq N Co-administration of a human rotavirus vaccine Rix4414 with DTPw-HBv vaccines: immunogenicity and reactogenicity in healthy infants 13th International Congress on Infectious Diseases; June 19-22. 2008; Kuala Lumpur, Malaysia 2008","DOI":"10.1016\/j.ijid.2008.05.195"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0072|cit72","unstructured":"Phase IIIb, double blind, randomised, placebo-controlled, multi-country\/centre, study to assess safety, reactogenicity & immunogenicity of 2 doses of GSK Biologicals' oral live attenuated Human Rotavirus (HRV) vaccine in pre-term infants www.gsk-studyregister.com\/study\/3064"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0073|cit73","unstructured":"Phase IIIb, double blind, randomised, placebo-controlled, multi-country\/centre, study to assess safety, reactogenicity & immunogenicity of 2 doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in pre-term infants clinicaltrials.gov\/show\/NCT00420745"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/INF.0b013e3182490a2c","article-title":"Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European infants: a randomized phase IIIb study","volume":"31","author":"Omenaca","year":"2012","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0075|cit75","unstructured":"Emmanuel B Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants Asian Congress on Pediatric Infectious Diseases (ACPID); 2-4 September 2004; Kota Kinabula, Malaysia 2004"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0076|cit76","unstructured":"Phua KB Immunogenicity and reactogenicity of two doses of an oral human rotavirus (HRV) vaccine at different concentrations in healthy infants from Singapore 11th Asia Pacific Congress of Pediatrics and the 3rd Asia Pacific Congress of Pediatric Nursing; 2003; Bangkok, Thailand 2003"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0077|cit77","unstructured":"Phua KB Intussusception in children: a seven-year experience in Singapore 24th International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico 2004"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0078|cit78","unstructured":"Vesikari T High efficacy of two doses of Rotarix\u2122 (RIX4414) against rotavirus disease in Europe, Latin-America and Asia Asian Congress on Pediatric Infectious Diseases (ACPID); 2006 March 07-10; Cebu, Philippines 2006"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0079|cit79","unstructured":"De Vos B Gillard P Cheuvart B RIX4414 vaccine efficacy against rotavirus gastroenteritis due to G2P[4] strain 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA 2006"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD008521.pub6-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/01.inf.0000142370.16514.4a","article-title":"A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis","volume":"23","author":"De Vos","year":"2004","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0081|cit81","unstructured":"Emmanuel S Phua KB Goh P Quak SH Datta SK Han HH Immunogenicity of an acellular pertussis combination vaccine co-administered with a novel rotavirus vaccine in Singaporean infants 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain 2005"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0082|cit82","unstructured":"A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine at different viral concentrations (104.7, 105.2 and 106.1 foci forming units (ffu)) in healthy infants previously uninfected with human rotavirus and approximately three months of age, when administered concurrently with DTPa-IPV\/Hib and HBV vaccines www.gsk-studyregister.com\/study\/6785"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0083|cit83","unstructured":"A study to assess the efficacy, immunogenicity and safety of 2 doses of oral live attenuated human rotavirus vaccine (Rotarix) at different viral concentrations in healthy infants clinicaltrials.gov\/ct2\/show\/record\/NCT00429481"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.47102\/annals-acadmedsg.V35N1p38","article-title":"A rotavirus vaccine for prophylaxis of infant rotavirus gastroenteritis: the Asian experience","volume":"35","author":"Phua","year":"2006","journal-title":"Annals of the Academy of Medicine, Singapore"},{"issue":"18","key":"10.1002\/14651858.CD008521.pub6-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1016\/j.vaccine.2006.03.040","article-title":"A short report on highlights of worldwide development of RIX4414: a Singaporean experience","volume":"24","author":"Phua","year":"2006","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0086|cit86","unstructured":"Phua KB Quak SH Emmanuel S Goh PSC Han HH Hardt K Highlights of world-wide development: a Singapore experience 3rd International Conference on Vaccines for Enteric Diseases (VED) 28-30 April 2004; Montego Bay, Jamaica 2004"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1086\/431511","article-title":"Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants","volume":"192","author":"Phua","year":"2005","journal-title":"Journal of Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD008521.pub6-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"546","DOI":"10.47102\/annals-acadmedsg.V37N7p546","article-title":"Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b combination vaccine in a placebo-controlled rotavirus vaccine study","volume":"37","author":"Phua","year":"2008","journal-title":"Annals of the Academy of Medicine, Singapore"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0089|cit89","doi-asserted-by":"crossref","unstructured":"Vesikari T RIX4414: a new attenuated human rotavirus vaccine 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain 2005","DOI":"10.1097\/01.inf.0000141722.10130.50"},{"issue":"18","key":"10.1002\/14651858.CD008521.pub6-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/j.vaccine.2013.03.001","article-title":"Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial","volume":"31","author":"Lau","year":"2013","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0091|cit91","unstructured":"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants clinicaltrials.gov\/show\/NCT00197210"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0092|cit92","unstructured":"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine in healthy infants clinicaltrials.gov\/show\/NCT00329745"},{"issue":"30","key":"10.1002\/14651858.CD008521.pub6-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1016\/j.vaccine.2012.03.030","article-title":"Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population","volume":"30","author":"Phua","year":"2012","journal-title":"Vaccine"},{"issue":"43","key":"10.1002\/14651858.CD008521.pub6-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1016\/j.vaccine.2009.07.098","article-title":"Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study","volume":"27","author":"Phua","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"44","DOI":"10.47102\/annals-acadmedsg.V45N2p44","article-title":"Efficacy, immunogenicity and safety of a human rotavirus vaccine RIX4414 in Singaporean infants","volume":"45","author":"Phua","year":"2016","journal-title":"Annals of the Academy of Medicine, Singapore"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0096|cit96","unstructured":"Immunization of infants 6-14 weeks of age, with GlaxoSmithKline Biologicals Rotavirus vaccine to explore the existence of transmission of rotavirus vaccine strain between twins in a family clinicaltrialsregister.eu\/ctr-search\/trial\/2015-001542-29\/results"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0097|cit97","unstructured":"A Phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family clinicaltrials.gov\/show\/NCT00396630"},{"issue":"51","key":"10.1002\/14651858.CD008521.pub6-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1016\/j.vaccine.2011.10.015","article-title":"Horizontal transmission of a human rotavirus vaccine strain - a randomized, placebo-controlled study in twins","volume":"29","author":"Rivera","year":"2011","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0099|cit99","unstructured":"Costa Clemens SA Operational organization of a large scale phase III clinical trial of rotavirus vaccine in multiple sites and countries in Latin America International Congress of Pediatrics (ICP); 2004 August 15-20; Cancun, Mexico 2004"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0100|cit100","unstructured":"De Vos B Rotarix\u2122: an effective way to prevent rotavirus diarrhoea and vomiting 9th Congress of the Asian Pan Pacific Society of Paediatric Gastroenterology, Hepatology and Nutrition & 27th Annual Congress of the Malaysian Paediatric Association; 2005 June 16-19; Kuala Lumpur, Malaysia 2005"},{"issue":"8","key":"10.1002\/14651858.CD008521.pub6-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1080\/21645515.2017.1320007","article-title":"Background rates of disease in Latin American children from a rotavirus vaccine study","volume":"13","author":"Baay","year":"2017","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0102|cit102","unstructured":"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants (efficacy data from visit 1 to visit 4) www.gsk-studyregister.com\/study\/6791"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0103|cit103","unstructured":"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants (2nd year efficacy from visit 4 to visit 6) www.gsk-studyregister.com\/study\/6791"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0104|cit104","unstructured":"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants (safety for the period between visit 1 and visit 3) www.gsk-studyregister.com\/study\/6791"},{"issue":"7","key":"10.1002\/14651858.CD008521.pub6-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1590\/S0074-02762012000700002","article-title":"Oral live attenuated human rotavirus vaccine (Rotarix) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children","volume":"107","author":"Justino","year":"2012","journal-title":"Memorias do Instituto Oswaldo Cruz"},{"issue":"9619","key":"10.1002\/14651858.CD008521.pub6-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(08)60524-3","article-title":"Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study","volume":"371","author":"Linhares","year":"2008","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0107|cit107","unstructured":"Lopez P Linhares A P\u00e9rez-Schael I Ruiz-Palacios G Costa Clemens S Sanchez N Early protection against severe rotavirus gastroenteritis - RIX4414 experience in Latin America 24th Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2006 May 03-05; Basel, Switzerland 2006"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0108|cit108","unstructured":"Macias M Lopez P Velazquez FR Vergara RF Salmeron J Tavares JL The rotavirus vaccine RIX4414 (Rotarix) is not associated with intussusception in one year old infants 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA 2005"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0109|cit109","unstructured":"A multi-country & multi-center study to assess the efficacy, immunogenicity & safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants clinicaltrials.gov\/ct2\/show\/NCT00139347"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0110|cit110","unstructured":"Placebo-controlled, multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants clinicaltrials.gov\/ct2\/show\/NCT00140673"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0111|cit111","unstructured":"Perez-Schael I Linhares AC Vesikari T Two doses of the human attenuated rotavirus vaccine RIX4414 (Rotarix) show heterotypic protection in Latin America and Europe 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA 2005"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0112|cit112","first-page":"143","article-title":"New rotavirus vaccine is effective and appears to have no increased risk of intussusception","volume":"149","author":"Pike","year":"2006","journal-title":"Clinical Research Abstracts For Pediatricians"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0113|cit113","unstructured":"Ruiz-Palacios G Aranza C Velazquez FR Richardson V Nandi E Macias M Two doses of the human-attenuated monovalent G1P[8] rotavirus vaccine, Rotarix show high efficacy in Mexican children against severe rotavirus gastroenteritis and severe overall gastroenteritis 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2005 December 16-19; Washington DC, USA 2005"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa052434","article-title":"Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis","volume":"354","author":"Ruiz-Palacios","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0115|cit115","unstructured":"Vel\u00e1zquez FR Abat H Costa Clemens SA Espinoza F Gillard P Linhares AC The human monovalent G1P[8] rotavirus vaccine, Rotarix is highly efficacious and provides crossprotection against G1 and non-G1 serotypes 23rd Annual meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain 2005"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0116|cit116","unstructured":"Vel\u00e1zquez RF Abate H Bouckenooghe A RIX4414, the human G1P[8] rotavirus vaccine is highly efficacious during the second year of life 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 September 27-30; San Francisco, USA 2006"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0117|cit117","unstructured":"Vesikari T O\u2019Ryan M Abate H Costa Clemens SA Espinoza F Gillard P Overcoming the safety hurdle: the rotavirus vaccine RIX4414 is not associated with intussusception 23rd Annual Meeting of European Society for Paediatric Infectious Diseases (ESPID); 2005 May 18-20; Valencia, Spain 2005"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0118|cit118","unstructured":"Ruiz-Palacios G Guerrero L Linhares AC Efficacy of an oral human rotavirus (HRV) vaccine in preventing diarrhoea due to G1 and non-G1 rotavirus [Presentation] 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile 2002"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0119|cit119","unstructured":"Ruiz-Palacios G Guerrero ML Linhares AC Two-year efficacy of GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster] 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico 2004"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0120|cit120","unstructured":"Salinas B Perez-Schael I Ruiz-Palacios G Early protection by GlaxoSmithKline Biologicals' live attenuated rotavirus vaccine in Latin American children [poster] 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico 2004"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0121|cit121","unstructured":"Salinas B Tomat MA Yarzabal JP Efficacy of the rotavirus vaccine (RIX4414) among infants in Carabobo State, Venezuela [poster] Asocaci\u00f3n Venezolana para el Avance de la Cienca (AsoVAC); 2004; Venezuela 2004"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0122|cit122","first-page":"217","article-title":"Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants","volume":"83","author":"Araujo","year":"2007","journal-title":"Jornal de Pediatria"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0123|cit123","unstructured":"De Vos B Hardt K Linhares AC Ruiz-Palacios G Guerrero L Salinas B Efficacy of two doses of a human monovalent rotavirus vaccine, Rotarix\u2122 in preventing gastro-enteritis due to G1 and Non-G1 rotavirus in Brazil, Mexico and Venezuela [presentation] 8th International Symposium on Double-Stranded RNA Viruses; 2003 September 13-18; Lucca, Italy 2003"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD008521.pub6-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/01.inf.0000142370.16514.4a","article-title":"A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis","volume":"23","author":"De Vos","year":"2004","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0125|cit125","unstructured":"A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines www.gsk-studyregister.com\/study\/6784"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0126|cit126","unstructured":"A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated human rotavirus (HRV) vaccine at different virus concentrations (104.7, 105.2 and 105.8 foci forming units [ffu]) in healthy infants (approximately 2 months of age at first dose) following a 0, 2 month schedule and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines [This summary presents results for the second and combined efficacy periods and results from the 3-Dose subset. Results from the first efficacy period are presented in 444563\/006 (Rota-006) summary] www.gsk-studyregister.com\/study\/6784"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0127|cit127","unstructured":"Linhares A Perez-Schael I Ruiz-Palacios M Pernambuco E Jacquet J De Vos B Immunogenicity and reactogenicity of an oral human rotavirus (HRV) vaccine in Latin American infants [poster] 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile 2002"},{"issue":"18","key":"10.1002\/14651858.CD008521.pub6-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1016\/j.vaccine.2005.07.027","article-title":"A short report on highlights of world-wide development of RIX4414: a Latin American experience","volume":"24","author":"Linhares","year":"2006","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1086\/505493","article-title":"Rotavirus serotype G9 is associated with more-severe disease in Latin America","volume":"43","author":"Linhares","year":"2006","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0130|cit130","unstructured":"To assess the efficacy, immuno & safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months & previously uninfected with HRV, concurrently given with DTPw-HBV, Hib clinicaltrials.gov\/show\/NCT00385320"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0131|cit131","unstructured":"Perez-Schael I Salinas B Linhares A Guerrero M Ruiz-Palacios G Clemens S Protective efficacy of an oral human rotavirus (HRV) vaccine in Latin American infants [poster] 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC); San Diego, 27-30 September 2002 2002 18, LB 23"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1086\/519687","article-title":"Efficacy of the human rotavirus vaccine RIX4414 in malnourished children","volume":"196","author":"Perez-Schael","year":"2007","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1542\/peds.2006-2630","article-title":"Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican infants","volume":"120","author":"Ruiz-Palacios","year":"2007","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0134|cit134","unstructured":"Ruiz-Palacios GM Impact of maternal antibodies on the immune response to an oral human rotavirus (HRV) vaccine in Mexican infants [presentation] 3rd World Congress of Pediatric Infectious Diseases; 2002 November 19-23; Santiago, Chile 2002"},{"issue":"9","key":"10.1002\/14651858.CD008521.pub6-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/01.inf.0000178294.13954.a1","article-title":"Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: a randomized, placebo-controlled trial in Latin American infants","volume":"24","author":"Salinas","year":"2005","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0136|cit136","unstructured":"A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa www.gsk-studyregister.com\/study\/6787"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0137|cit137","unstructured":"A phase II, double blind randomised, placebo controlled study to assess the safety reactogenicity and immunogenicity of three doses of GSK Biologicals (South Africa) controlled-trials.com\/ISRCTN86632774"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0138|cit138","unstructured":"Reactogenicity & immunogenicity study of two doses of GSK Biologicals\u2019 oral live attenuated HRV vaccine co-administered with either OPV or IPV in healthy infants (approximately 5-10 weeks old) in South Africa clinicaltrials.gov\/show\/NCT00346892"},{"issue":"39","key":"10.1002\/14651858.CD008521.pub6-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1016\/j.vaccine.2008.08.034","article-title":"Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines","volume":"28","author":"Steele","year":"2010\u00a0","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0140|cit140","unstructured":"Steele AD Tumbo J Armah G Reynders J Scholtz F Bos P Immunogenicity and reactogenicity of a new live attenuated oral rotavirus vaccine (RIX4414) when administered concurrently with poliovirus vaccines in African infants 24th International Congress of Pediatrics; 2004 August 15-20; Cancun, Mexico 2004"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0141|cit141","unstructured":"Steele AD Tumbo JM Armah GE Reynders J Scholtz F Bos P Concomitant administration of a live-attenuated oral rotavirus vaccine (RIX4414) with poliovirus vaccines in African infants 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases - ESPID; 2005 May 18-20; Valencia, Spain 2005"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0142|cit142","unstructured":"A phase II study to assess the safety and immunogenicity of GlaxoSmithKline Biologicals rotavirus vaccine, RIX4414 when administered to HIV infected infants in South Africa www.clinicaltrialsregister.eu\/ctr-search\/trial\/2015-001484-39\/results"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0143|cit143","unstructured":"A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine www.gsk-studyregister.com\/study\/6790"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0144|cit144","unstructured":"A phase II, double-blind, randomised, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) administered to human immunodeficiency virus (HIV) infected infants at 6, 10 and 14 weeks of age in South Africa www.controlled-trials.com\/ISRCTN11877362"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0145|cit145","unstructured":"A study of safety, reactogenicity and immunogenicity of HRV vaccine in HIV infected infants in South Africa clinicaltrials.gov\/ct2\/show\/results\/NCT00263666"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/INF.0b013e3181f42db9","article-title":"Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa","volume":"30","author":"Steele","year":"2011","journal-title":"Pediatric Infectious Diseases Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0147|cit147","unstructured":"A phase II, double-blind before the 2002 rotavirus season and single blind with respect to OPV after, randomised, placebo-controlled study of the safety, reactogenicity and immunogenicity of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 105 ffu) co-administered with either oral polio vaccine (OPV) or inactivated polio vaccine (IPV) in healthy infants (approximately 5-10 weeks old) in South Africa www.gsk-studyregister.com\/study\/6786"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0148|cit148","unstructured":"A double blind, randomised placebo controlled study of the safety, reactogenicity and immunogenicity of two doses of orally administered human rotavirus vaccine (RIX4414) in healthy infants in South Africa controlled-trials.com\/ISRCTN37373664"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0149|cit149","unstructured":"A study of the safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants (approximately 5-10 weeks old) in South Africa clinicaltrials.gov\/show\/NCT00383903"},{"issue":"Suppl","key":"10.1002\/14651858.CD008521.pub6-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1086\/653550","article-title":"Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants","volume":"202","author":"Steele","year":"2010","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0151|cit151","unstructured":"A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, immunogenicity and safety of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants www.gsk-studyregister.com\/study\/6792"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0152|cit152","unstructured":"Gonzalez Ayala S Rivera L Rivera-Medina DM Lopez P Valencia A De Le\u00f3n T Co-administration with rotavirus vaccine rix4414 (Rotarix\u2122) does not interfere with the immunogenicity of oral polio vaccine (OPV) [poster] World Society for Pediatric Infectious Diseases (WSPID); 2007 November 15-18; Bangkok, Thailand 2007"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/INF.0b013e3182138278","article-title":"Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America","volume":"30","author":"Tregnaghi","year":"2011","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0154|cit154","unstructured":"A phase II, double-blind, randomized, placebo-controlled, dose-escalating, stepwise study to assess safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals\u2019 live attenuated human rotavirus (HRV) vaccine in healthy infants previously uninfected with human rotavirus www.gsk-studyregister.com\/study\/6781"},{"issue":"21-2","key":"10.1002\/14651858.CD008521.pub6-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1016\/j.vaccine.2004.01.044","article-title":"Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants","volume":"22","author":"Vesikari","year":"2004","journal-title":"Vaccine"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD008521.pub6-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/01.inf.0000142370.16514.4a","article-title":"A rotavirus vaccine for prophylaxis of infants against rotavirus gastroenteritis","volume":"23","author":"De Vos","year":"2004","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0157|cit157","unstructured":"A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [Results for the first efficacy period (starting from 2 weeks after dose 2 until the end of the first RV season following vaccination)] www.gsk-studyregister.com\/study\/6782"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0158|cit158","unstructured":"A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV [This summary presents results for the second efficacy period (from the end of the first rotavirus season post-vaccination until the end of the second rotavirus season) and for the two consecutive rotavirus seasons] www.gsk-studyregister.com\/study\/6782"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0159|cit159","unstructured":"A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants clinicaltrials.gov\/show\/NCT00425737"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0160|cit160","unstructured":"Vesikari T Karvonen A Espo M Korhonen T Delem A De Vos B Efficacy evaluation of an oral human rotavirus (HRV) vaccine in previously uninfected Finnish infants 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 September 27-30; San Diego, California 2002"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/01.inf.0000141722.10130.50","article-title":"Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants","volume":"23","author":"Vesikari","year":"2004","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0162|cit162","unstructured":"Vesikari T Human rotavirus vaccine Rotarix is highly efficacious in Europe 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland 2006"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0163|cit163","unstructured":"Vesikari T Rotarix, an oral human Rotavirus vaccine, is highly immunogenic in healthy infants from 6 European countries 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland 2006"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0164|cit164","unstructured":"A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results from the first efficacy period] [102247-036] www.gsk-studyregister.com\/study\/2669"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0165|cit165","unstructured":"A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [This summary presents results for the second and combined efficacy periods] www.gsk-studyregister.com\/study\/2669"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0166|cit166","unstructured":"A phase IIIb, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccinations [A phase IIIb open study to assess the long-term efficacy and safety of GlaxoSmithKline (GSK) Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine approximately three years after vaccination in healthy infants aged 6-12 weeks at the time of first vaccination in the Rota-036 study (eTrack No.102247) in Finland] www.gsk-studyregister.com\/study\/2669"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0167|cit167","unstructured":"A multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine in healthy infants in co-administration with specific childhood vaccines clinicaltrials.gov\/ct2\/show\/record\/NCT00140686"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0168|cit168","unstructured":"To assess long-term efficacy & safety of subjects approximately 3 years after priming with 2 doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in the primary vaccination study (102247) clinicaltrials.gov\/show\/NCT00420316"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0169|cit169","unstructured":"Schuster V Otto W Cohen R RotarixTM an oral human Rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland 2006"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0170|cit170","unstructured":"Tejedor JC Diez-Delegado J Aristegui J Rotarix (RIX4414), an oral Human Rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitides Serogroup C vaccine (MeningitecTM) in healthy infants from Spain 24th Annual Meeting Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland 2006"},{"issue":"32","key":"10.1002\/14651858.CD008521.pub6-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1016\/j.vaccine.2010.05.057","article-title":"Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe","volume":"28","author":"Vesikari","year":"2010","journal-title":"Vaccine"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/INF.0b013e3181e28e6e","article-title":"Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine","volume":"29","author":"Vesikari","year":"2010","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"9601","key":"10.1002\/14651858.CD008521.pub6-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(07)61744-9","article-title":"Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study","volume":"370","author":"Vesikari","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/INF.0b013e3182489cac","article-title":"Efficacy and immunogenicity of live-attenuated human rotavirus vaccine in breast-fed and formula-fed European infants","volume":"31","author":"Vesikari","year":"2012","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0175|cit175","unstructured":"Vesikari T Prymula R Schuster V Early protection against Rotavirus, Rotarix, experience in an European setting 12th International Congress for Infectious Diseases; 2006 June 15-18; Lisbon, Portugal 2006"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0176|cit176","unstructured":"Vesikari T Prymula R Schuster V Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphteria-tetanus-pertussis (DTPA)-combined vaccines in healthy infants from Europe 24th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2006 June 15-18; Basel, Switzerland 2006"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0177|cit177","unstructured":"Vesikari T Immunogenicity of liquid formulation of the oral live attenuated human rotavirus vaccine (Rotarix\u2122) [poster] Sociedad Latinoamericana de Infectolog\u00eda Pedi\u00e1trica (SLIPE). San Jose, Costa Rica 8-11 May 2007"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0178|cit178","unstructured":"A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals\u2019 live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV www.gsk-studyregister.com\/study\/2783"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0179|cit179","unstructured":"Compare the immunogenicity, reactogenicity & safety of 2 different formulations of GSK Biologicals\u2019 live attenuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV clinicaltrials.gov\/ct2\/show\/record\/NCT00137930"},{"issue":"11","key":"10.1002\/14651858.CD008521.pub6-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.vaccine.2011.01.004","article-title":"Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 oral suspension (liquid formulation) in Finnish infants","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"issue":"12","key":"10.1002\/14651858.CD008521.pub6-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1086\/509623","article-title":"Reductions in cross-neutralizing antibody responses in infants after attenuation of the human rotavirus vaccine candidate 89-12","volume":"194","author":"Ward","year":"2006","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0182|cit182","unstructured":"A phase II, randomised, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GSK Biologicals\u2019 oral live attenuated human rotavirus (HRV) vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus when given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh www.gsk-studyregister.com\/study\/2748"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0183|cit183","unstructured":"Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals\u2019 oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh clinicaltrials.gov\/show\/NCT00139334"},{"issue":"9","key":"10.1002\/14651858.CD008521.pub6-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.vaccine.2008.12.059","article-title":"Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age","volume":"27","author":"Zaman","year":"2009","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"e1002282","DOI":"10.1371\/journal.pmed.1002282","article-title":"Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: a cluster-randomized trial","volume":"14","author":"Zaman","year":"2017","journal-title":"PLOS Medicine"},{"issue":"25","key":"10.1002\/14651858.CD008521.pub6-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1016\/j.vaccine.2018.05.023","article-title":"Safety of a heat-stable rotavirus vaccine among children in Niger: data from a phase 3, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Coldiron","year":"2018","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJMc1705793","article-title":"Heat-stable oral rotavirus vaccine","volume":"377","author":"Isanaka","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD008521.pub6-BIB0188|cit188","first-page":"242","article-title":"Efficacy and safety of a low-cost, heat-stable oral roatvirus vaccine agains severe rotavirus gastroenteritis in Niger","volume":"95","author":"Isanaka","year":"2017","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"12","key":"10.1002\/14651858.CD008521.pub6-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMoa1609462","article-title":"Efficacy of a low-cost, heat-stable oral Rotavirus vaccine in Niger","volume":"376","author":"Isanaka","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0190|cit190","doi-asserted-by":"crossref","unstructured":"Isanaka S Langendorf C McNeal MM Meyer N Plikaytis B Garba S Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: a randomized controlled clinical trial (unpublished manuscript received via email correspondence from Rebecca Grais to Nicholas Henschke on 19 August 2020) data on file","DOI":"10.1371\/journal.pmed.1003655"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0191|cit191","unstructured":"Efficacy and safety of a pentavalent Rotavirus vaccine (BRV-PV) against severe rotavirus gastroenteritis in Niger (ROSE) clinicaltrials.gov\/ct2\/show\/NCT02145000"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0192|cit192","unstructured":"A clinical trial to study the effect and safety of Rotavirus vaccine against severe Rotavirus gastroenteritis in healthy Indian Infants www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=5518&EncHid=&modid=&compid=%27,%275518det%27"},{"issue":"45","key":"10.1002\/14651858.CD008521.pub6-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"6228","DOI":"10.1016\/j.vaccine.2017.09.014","article-title":"A randomized phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants","volume":"35","author":"Kulkarni","year":"2017","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0194|cit194","unstructured":"A clinical trial to study the effect and safety of Rotavirus vaccine against severe rotavirus gastroenteritis in healthy Indian infants clinicaltrials.gov\/ct2\/show\/NCT02133690"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0195|cit195","unstructured":"A randomized, double-blind, placebo controlled study to assess the safety and tolerability of rotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine) ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=987&EncHid=&modid=&compid=%27,%27987det%27"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0196|cit196","doi-asserted-by":"publisher","first-page":"A124","DOI":"10.1016\/j.vaccine.2014.03.003","article-title":"Bovine rotavirus pentavalent vaccine development in India","volume":"32","author":"\u00a0Kulkarni","year":"2014","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0197|cit197","unstructured":"A randomized, double-blind, placebo controlled study to assess the safety and tolerability of RotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine) ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=987&EncHid=&modid=&compid=%27,%27987det%27"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0198|cit198","doi-asserted-by":"publisher","first-page":"A124","DOI":"10.1016\/j.vaccine.2014.03.003","article-title":"Bovine rotavirus pentavalent vaccine development in India","volume":"32","author":"\u00a0Kulkarni","year":"2014","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0199|cit199","unstructured":"A randomized, double-blind, placebo controlled study to assess safety and tolerability of RotaVac vaccine (live attenuated bovine-human (UK) reassortant pentavalent rotavirus vaccine) ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=2458&EncHid=&modid=&compid=%27,%272458det%27"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0200|cit200","doi-asserted-by":"publisher","first-page":"A124","DOI":"10.1016\/j.vaccine.2014.03.003","article-title":"Bovine rotavirus pentavalent vaccine development in India","volume":"32","author":"\u00a0Kulkarni","year":"2014","journal-title":"Vaccine"},{"issue":"9741","key":"10.1002\/14651858.CD008521.pub6-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Armah","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"A86","DOI":"10.1016\/j.vaccine.2011.10.006","article-title":"Immunogenicity of the pentavalent rotavirus vaccine in African infants","volume":"30","author":"Armah","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/j.vaccine.2011.08.124","article-title":"Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine","volume":"30","author":"Breiman","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/INF.0000000000001362","article-title":"Heterogeneity of rotavirus vaccine efficacy among infants in developing countries","volume":"36","author":"Gruber","year":"2017","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"14658","DOI":"10.1038\/srep14658","article-title":"Comparative analysis of pentavalent rotavirus vaccine strains and G8 rotaviruses identified during vaccine trial in Africa","volume":"5","author":"Heylen","year":"2015","journal-title":"Science Reports"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0206|cit206","unstructured":"Efficacy, safety, and immunogenicity of RotaTeq TM among infants in Asia and Africa clinicaltrials.gov\/ct2\/show\/record\/NCT00362648"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"A79","DOI":"10.1016\/j.vaccine.2012.01.022","article-title":"Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa","volume":"30","author":"Tapia","year":"2012","journal-title":"Vaccine"},{"issue":"9741","key":"10.1002\/14651858.CD008521.pub6-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Armah","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0209|cit209","doi-asserted-by":"crossref","first-page":"A79","DOI":"10.1016\/j.vaccine.2012.01.022","article-title":"Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa","volume":"30","author":"Tapia","year":"2012","journal-title":"Vaccine"},{"issue":"9741","key":"10.1002\/14651858.CD008521.pub6-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Armah","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"A52","DOI":"10.1016\/j.vaccine.2011.08.043","article-title":"Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya","volume":"30","author":"Feikin","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1016\/j.vaccine.2011.09.026","article-title":"Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq((R)), in Kenya, including among HIV-infected and HIV-exposed infants","volume":"30","author":"Laserson","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"A79","DOI":"10.1016\/j.vaccine.2012.01.022","article-title":"Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa","volume":"30","author":"Tapia","year":"2012","journal-title":"Vaccine"},{"issue":"9741","key":"10.1002\/14651858.CD008521.pub6-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(10)60889-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Armah","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"A71","DOI":"10.1016\/j.vaccine.2011.11.094","article-title":"Efficacy of the oral pentavalent rotavirus vaccine in Mali","volume":"30","author":"Sow","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"A79","DOI":"10.1016\/j.vaccine.2012.01.022","article-title":"Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa","volume":"30","author":"Tapia","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1542\/peds.2006-2058","article-title":"Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life","volume":"119","author":"Block","year":"2007","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0218|cit218","unstructured":"Study of the efficacy, safety, and immunogenicity of RotaTeq\u2122 at expiry potency NCT00092443 (PN 007) www.clinicalstudyresults.org\/drugdetails\/?indication_id=523&sort=c.company_name&page=1&drug_id=900"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0219|cit219","unstructured":"Study of the efficacy, safety, and immunogenicity of V260 at expiry clinicaltrials.gov\/ct2\/show\/NCT00092443"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/INF.0b013e31818c0161","article-title":"Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis\u00a0B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity","volume":"28","author":"Ciarlet","year":"2009","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0221|cit221","unstructured":"Safety and immunogenicity of concomitant use of RotaTeq\u2122 and INFANRIX\u2122 hexa in healthy infants NCT00258154 (PN 010) [Merck & Co. Inc. Study Synopsis] clinicalstudyresults.org\/drugdetails\/?indication_id=1101&sort=c.company_name&page=1&drug_id=2823"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0222|cit222","unstructured":"Safety and immunogenicity of concomitant use of V260 and INFANRIX(Tm) hexa in healthy infants clinicaltrials.gov\/show\/NCT00258154"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/01.inf.0000091887.48999.77","article-title":"Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer\/buffer liquid formulation","volume":"22","author":"Clark","year":"2003","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0224|cit224","first-page":"172A","article-title":"Preliminary evaluation of safety and efficacy of quadrivalent human-bovine reassortant rotavirus vaccine [abstract]","volume":"37","author":"Clark","year":"1995","journal-title":"Pediatric Research"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jpeds.2003.10.054","article-title":"Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants","volume":"144","author":"Clark","year":"2004","journal-title":"Journal of Pediatrics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/infdis\/174.Supplement_1.S73","article-title":"The development of multivalent bovine rotavirus (strain WC3) reassortant vaccine for infants","volume":"174","author":"Clark","year":"1996","journal-title":"Journal of Infectious Diseases"},{"issue":"12","key":"10.1002\/14651858.CD008521.pub6-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1086\/421248","article-title":"Rotavirus immunoglobulin a responses stimulated by each of 3 doses of a quadrivalent human\/bovine reassortant rotavirus vaccine","volume":"189","author":"Ward","year":"2004","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0228|cit228","unstructured":"A study to evaluate safety of Rotavirus vaccine in healthy adult volunteers followed by safety, tolerability and immunogenicity evaluation in healthy infants ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=4929&EncHid=&userName=CTRI\/2012\/07\/002820"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"A117","DOI":"10.1016\/j.vaccine.2014.03.069","article-title":"Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants","volume":"32","author":"Dhingra","year":"2014","journal-title":"Vaccine"},{"issue":"8","key":"10.1002\/14651858.CD008521.pub6-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.4161\/hv.24846","article-title":"Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"9","author":"Iwata","year":"2013","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0231|cit231","unstructured":"A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan clinicaltrials.gov\/ct2\/show\/record\/NCT00718237"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/INF.0b013e31815aba79","article-title":"Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea","volume":"27","author":"Kim","year":"2008","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0233|cit233","unstructured":"Immunogenicity and safety of RotaTeq\u00ae in healthy infants in Korea - NCT00166517 (PN 013) clinicalstudyresults.org\/drugdetails\/?indication_id=523&sort=c.company_name&page=1&drug_id=2148"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0234|cit234","unstructured":"Immunogenicity and safety of V260 in healthy infants in Korea clinicaltrials.gov\/show\/NCT00166517"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1016\/j.ijid.2012.05.998","article-title":"A study of RotaTeqTM (pentavalent rotavirus vaccine) in Chinese healthy adults, children and infants","volume":"16","author":"Lawrence","year":"2012","journal-title":"International Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0236|cit236","unstructured":"A study of V260 in healthy Chinese adults, children and infants clinicaltrials.gov\/ct2\/show\/study\/NCT00953056"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/QAD.0000000000001258","article-title":"Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa","volume":"31","author":"Levin","year":"2017","journal-title":"AIDS"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0238|cit238","unstructured":"Safety and immunogenicity of a live, attenuated rotavirus (RotaTeq TM ) in HIV-1 infected and uninfected children born to HIV-1-infected mothers clinicaltrials.gov\/ct2\/show\/study\/NCT00880698"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0239|cit239","unstructured":"Uprety P Lindsey J Levin M Rainwater-Lovett K Ziemniak C Kaplan S Enhanced inflammation and rotavirus vaccine responses in perinatal HIV-1 infection Topics in Antiviral Medicine; 23rd Conference on Retroviruses and Opportunistic Infections, CROI; 2016, USA 2016 347"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0240|cit240","unstructured":"Protocol 009 - Comparison of the immunogenicity and safety of three consistency lots of RotaTeq\u2122 in healthy infants (NCT00092456) clinicalstudyresults.org\/drugdetails\/?indication_id=523&sort=c.company_name&page=1&drug_id=1357"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0241|cit241","unstructured":"Comparison of the immunogenicity and safety of three consistency lots of V260 in healthy infants clinicaltrials.gov\/ct2\/show\/record\/NCT00092456"},{"issue":"43","key":"10.1002\/14651858.CD008521.pub6-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1016\/j.vaccine.2017.08.081","article-title":"Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial","volume":"35","author":"Mo","year":"2017","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0243|cit243","unstructured":"Efficacy, safety, and immunogenicity of V260 in healthy Chinese infants (V260-024) clinicaltrials.gov\/show\/NCT02062385"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD008521.pub6-BIB0244|cit244","first-page":"307A","article-title":"The effect of dose and composition of a pentavalent rotavirus reassortant vaccine [RotaTeq (R)] in safety, efficacy, and immunogenicity in healthy infants","volume":"53","author":"Vesikari","year":"2003","journal-title":"Pediatric Research"},{"issue":"22","key":"10.1002\/14651858.CD008521.pub6-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1016\/j.vaccine.2006.03.025","article-title":"Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants","volume":"24","author":"Vesikari","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0929-6646(09)60067-X","article-title":"Experience of pentavalent human-bovine reassortant rotavirus vaccine among healthy infants in Taiwan","volume":"108","author":"Chang","year":"2009","journal-title":"Journal of the Formosan Medical Association"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"e1499","DOI":"10.1542\/peds.2010-1240","article-title":"Pentavalent rotavirus vaccine in developing countries: safety and health care resource utilization","volume":"126","author":"Christie","year":"2010","journal-title":"Pediatrics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008521.pub6-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S1201-9712(07)60020-4","article-title":"The integrated phase III safety profile of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"11","author":"Dennehy","year":"2007","journal-title":"International Journal of Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD008521.pub6-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/INF.0b013e318168d29e","article-title":"Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency","volume":"27","author":"Goveia","year":"2008","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"12","key":"10.1002\/14651858.CD008521.pub6-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/INF.0b013e31814521cb","article-title":"Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants","volume":"26","author":"Goveia","year":"2007","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/INF.0b013e3181be6257","article-title":"Efficacy and safety of pentavalent human-bovine reassortant rotavirus vaccine when administered with greater than 10 weeks between doses","volume":"29","author":"Goveia","year":"2010","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/MPG.0b013e318287c5cc","article-title":"Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine","volume":"56","author":"Grant","year":"2013","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/INF.0b013e3182435afe","article-title":"Efficacy of a pentavalent human-bovine reassortant rotavirus vaccine against rotavirus gastroenteritis among American Indian children","volume":"31","author":"Grant","year":"2012","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-2431-10-42","article-title":"Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)","volume":"10","author":"Itzler","year":"2010","journal-title":"BMC Pediatrics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0255|cit255","unstructured":"Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants NCT00090233 (PN 006) clinicalstudyresults.org\/drugdetails\/?indication_id=523&sort=c.company_name&page=1&drug_id=1144"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0256|cit256","unstructured":"Safety and efficacy of pentavalent (G1, G2, G3, G4, and P1) human-bovine reassortant rotavirus vaccine in healthy infants clinicaltrials.gov\/ct2\/show\/record\/NCT00090233"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.inf.0000254391.71103.e8","article-title":"Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States","volume":"26","author":"Rodriguez","year":"2007","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/INF.0b013e3181e28e6e","article-title":"Sustained efficacy of the pentavalent rotavirus vaccine, RV5, up to 3.1 years following the last dose of vaccine","volume":"29","author":"Vesikari","year":"2010","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.vaccine.2009.10.041","article-title":"RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe","volume":"28","author":"Vesikari","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD008521.pub6-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1201-9712(07)60019-8","article-title":"Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries)","volume":"11","author":"Vesikari","year":"2007","journal-title":"International Journal of Infectious Diseases"},{"issue":"11","key":"10.1002\/14651858.CD008521.pub6-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00431-010-1242-3","article-title":"Efficacy of the pentavalent rotavirus vaccine, RotaTeq(R), in Finnish infants up to 3 years of age: the Finnish Extension Study","volume":"169","author":"Vesikari","year":"2010","journal-title":"European Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"A24","DOI":"10.1016\/j.vaccine.2011.08.124","article-title":"Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine","volume":"30","author":"Breiman","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/INF.0000000000001362","article-title":"Heterogeneity of rotavirus vaccine efficacy among infants in developing countries","volume":"36","author":"Gruber","year":"2017","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0265|cit265","unstructured":"Efficacy, safety, and immunogenicity of RotaTeqTM among infants in Asia and Africa clinicaltrials.gov\/ct2\/show\/record\/NCT00362648"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"A106","DOI":"10.1016\/j.vaccine.2011.11.091","article-title":"Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam","volume":"30","author":"Shin","year":"2012","journal-title":"Vaccine"},{"issue":"9741","key":"10.1002\/14651858.CD008521.pub6-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Zaman","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"A101","DOI":"10.1016\/j.vaccine.2011.09.065","article-title":"Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh","volume":"30","author":"Feller","year":"2012","journal-title":"Vaccine"},{"issue":"9741","key":"10.1002\/14651858.CD008521.pub6-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Zaman","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"A94","DOI":"10.1016\/j.vaccine.2011.07.117","article-title":"Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh","volume":"30","author":"Zaman","year":"2012","journal-title":"Vaccine"},{"issue":"9741","key":"10.1002\/14651858.CD008521.pub6-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(10)60755-6","article-title":"Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial","volume":"376","author":"Zaman","year":"2010","journal-title":"Lancet"},{"issue":"31","key":"10.1002\/14651858.CD008521.pub6-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1016\/j.vaccine.2006.05.001","article-title":"Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial","volume":"24","author":"Bhandari","year":"2006","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0273|cit273","unstructured":"A double-blind randomised placebo controlled dose escalating phase Ib\/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age isrctn.com\/ISRCTN57452882"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0274|cit274","unstructured":"Safety and immunogenicity study of live attenuated Indian rotavirus vaccine candidate strains 116E and I321 in infants clinicaltrials.gov\/ct2\/show\/NCT00280111"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1086\/600104","article-title":"A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial","volume":"200","author":"Bhandari","year":"2009","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0276|cit276","unstructured":"A double-blind randomised placebo controlled dose escalating phase Ib\/IIa study to evaluate the safety and immunogenicity of live attenuated rotavirus vaccine 116E in healthy non-malnourished infants eight to 20 weeks of age isrctn.com\/ISRCTN57452882"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0277|cit277","unstructured":"Dose escalation study to evaluate oral rotavirus vaccine 116E live attenuated in healthy infants 8 to 20 weeks old clinicaltrials.gov\/ct2\/show\/NCT00439660"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"A110","DOI":"10.1016\/j.vaccine.2014.04.079","article-title":"Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian children in the second year of life","volume":"32","author":"Bhandari","year":"2014","journal-title":"Vaccine"},{"issue":"9935","key":"10.1002\/14651858.CD008521.pub6-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/S0140-6736(13)62630-6","article-title":"Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial","volume":"383","author":"Bhandari","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0280|cit280","unstructured":"A phase III clinical trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=1317"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0281|cit281","doi-asserted-by":"crossref","first-page":"A104","DOI":"10.1016\/j.vaccine.2014.03.036","article-title":"Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India","volume":"32","author":"John","year":"2014","journal-title":"Vaccine"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0282|cit282","first-page":"906","article-title":"Why was there no vaccine-associated intussusception in Indian rotavirus vaccine trial?","volume":"52","author":"John","year":"2015","journal-title":"Indian Pediatrics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0283|cit283","unstructured":"A phase III, randomized, double blind, placebo controlled trial to evaluate the protective efficacy of three doses of oral rotavirus vaccine (ORV) 116E, against severe rotavirus gastroenteritis in infants clinicaltrials.gov\/show\/NCT01305109"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"e00302","DOI":"10.1016\/j.heliyon.2017.e00302","article-title":"ROTAVAC does not interfere with the immune response to childhood vaccines in Indian infants: a randomized placebo controlled trial","volume":"3","author":"Chandola","year":"2017","journal-title":"Heliyon"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0285|cit285","unstructured":"A phase III study to evaluate the non-interference in the immune response of rotavac to childhood vaccines and to assess the clinical lot consistency ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=5870&EncHid=&modid=&compid=%27,%275870det%27"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.vaccine.2020.08.070","article-title":"Concomitant administration of a liquid formulation of human rotavirus vaccine (porcine circovirus-free) with routine childhood vaccines in infants in the United States: results from a phase 3, randomized trial","volume":"39","author":"Abu-Elyazeed","year":"2020","journal-title":"Vaccine"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/infdis\/jit174","article-title":"Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period","volume":"208","author":"Armah","year":"2013","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0288|cit288","unstructured":"RV3-BB rotavirus vaccine phase IIa clinical trial of immunogenicity and safety anzctr.org.au\/ACTRN12611001212943.aspx"},{"issue":"12","key":"10.1002\/14651858.CD008521.pub6-BIB0289|cit289","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1473-3099(15)00227-3","article-title":"Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"Bines","year":"2015","journal-title":"Lancet Infectious Diseases"},{"issue":"8","key":"10.1002\/14651858.CD008521.pub6-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa1706804","article-title":"Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from birth","volume":"378","author":"Bines","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0291|cit291","first-page":"11","article-title":"Use of a rapid rotavirus test in prescription of antibiotics in acute diarrhea in pediatrics: an observational, randomized, controlled study","volume":"32","author":"Bucher","year":"2012","journal-title":"Revista de Gastroenterologia del Peru"},{"issue":"8","key":"10.1002\/14651858.CD008521.pub6-BIB0292|cit292","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1080\/21645515.2017.1323591","article-title":"Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine","volume":"13","author":"Cowley","year":"2017","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"49","key":"10.1002\/14651858.CD008521.pub6-BIB0293|cit293","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1016\/j.vaccine.2019.09.071","article-title":"Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB)","volume":"37","author":"Cowley","year":"2019","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0294|cit294","first-page":"A114","article-title":"A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children","volume":"30","author":"Dang","year":"2012","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0295|cit295","unstructured":"A dose-escalating study to evaluate the immunogenicity and safety of rotavin-M1 vaccine in healthy infants clinicaltrials.gov\/ct2\/show\/NCT01377571"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0296|cit296","unstructured":"A phase IV immunogenicity and safety study of BBILs oral rotavirus vaccine 116E (ROTAVAC) ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=7937&EncHid=&modid=&compid=%27,%277937det%27"},{"issue":"8","key":"10.1002\/14651858.CD008521.pub6-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(17)30242-6","article-title":"Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial","volume":"17","author":"Groome","year":"2017","journal-title":"Lancet Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD008521.pub6-BIB0298|cit298","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S1473-3099(20)30001-3","article-title":"Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Groome","year":"2020","journal-title":"Lancet Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/21645515.2019.1664239","article-title":"A randomized Phase I\/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants","volume":"16","author":"Kanchan","year":"2020","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"51","key":"10.1002\/14651858.CD008521.pub6-BIB0300|cit300","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1016\/j.vaccine.2011.10.015","article-title":"Horizontal transmission of a human rotavirus vaccine strain - a randomized, placebo-controlled study in twins","volume":"29","author":"Rivera","year":"2011","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0301|cit301","doi-asserted-by":"publisher","first-page":"jiaa210","DOI":"10.1093\/infdis\/jiaa210","article-title":"Immunogenicity and safety of porcine circovirus-free human rotavirus vaccine in healthy infants: a phase III, randomized trial","author":"Salamanca de la Cueva","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"46","key":"10.1002\/14651858.CD008521.pub6-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"7393","DOI":"10.1016\/j.vaccine.2020.04.038","article-title":"Efficacy, immunogenicity and safety of a trivalent live human-lamb reassortant rotavirus vaccine (LLR3) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial","volume":"38","author":"Xia","year":"2020","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1080\/21645515.2016.1267082","article-title":"Comparison of iatrogenic pain between rotavirus vaccination before and after vaccine injection in 2-month-old infants","volume":"13","author":"Yin","year":"2017","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"e20152603","DOI":"10.1542\/peds.2015-2603","article-title":"Safety and immunogenicity of sequential rotavirus vaccine schedules","volume":"137","author":"Libster","year":"2016","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0305|cit305","unstructured":"Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedule clinicaltrials.gov\/ct2\/show\/NCT01266850"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"e0127622 Correc","DOI":"10.1371\/journal.pone.0127622","article-title":"Impact of withholding breastfeeding at the time of vaccination on the immunogenicity of oral rotavirus vaccine - a randomized trial","volume":"10","author":"Ali","year":"2015","journal-title":"PLOS One"},{"issue":"11","key":"10.1002\/14651858.CD008521.pub6-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/infdis\/jiu335","article-title":"Impact of different dosing schedules on the immunogenicity of the human rotavirus vaccine in infants in Pakistan: a randomized trial","volume":"210","author":"Ali","year":"2014","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0308|cit308","unstructured":"The immunogenicity of rotavirus vaccine under different age schedules and the impact of withholding breast feeding around the time of vaccination on the immunogenicity of Rotarix vaccine clinicaltrials.gov\/show\/NCT01199874"},{"issue":"11","key":"10.1002\/14651858.CD008521.pub6-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/infdis\/jiw023","article-title":"A randomized, controlled trial of the impact of alternative dosing schedules on the immune response to human rotavirus vaccine in rural Ghanaian infants","volume":"213","author":"Armah","year":"2016","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0310|cit310","unstructured":"Evaluation of the human rotavirus vaccine when given at varying schedules in rural Ghana clinicaltrials.gov\/show\/NCT01575197"},{"issue":"9","key":"10.1002\/14651858.CD008521.pub6-BIB0311|cit311","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2020.01.041","article-title":"Impact of vaccination on the risk factors for acute rotavirus diarrhea: an analysis of the data of a cluster randomized trial conducted in a rural area of Bangladesh","volume":"38","author":"Aziz","year":"2020","journal-title":"Vaccine"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"e1062","DOI":"10.1542\/peds.2008-1059","article-title":"Coadministration of RIX4414 oral human rotavirus vaccine does not impact the immune response to antigens contained in routine infant vaccines in the United States","volume":"122","author":"Dennehy","year":"2008","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0313|cit313","unstructured":"Assess the immunogenicity of 3 doses of Pediarix\u00ae, Prevnar\u00ae & ActHIB\u00ae given to healthy infants when administered with GSK Biologicals\u2019 2 dose oral live attenuated human rotavirus vaccine given during the same vaccination visit or separately clinicaltrials.gov\/show\/NCT00334607"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/cid\/civ807","article-title":"Interference of monovalent, bivalent, and trivalent oral poliovirus vaccines on monovalent rotavirus vaccine immunogenicity in rural Bangladesh","volume":"62","author":"Emperador","year":"2016","journal-title":"Clinical Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0315|cit315","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1080\/21645515.2018.1564441","article-title":"Immunogenicity and safety of the diphtheria, pertussis, tetanus and inactivated poliovirus vaccine when co-administered with the human rotavirus vaccine (Rotarix) in healthy Japanese infants: a phase IV randomized study","volume":"15","author":"Gillard","year":"2019","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/infdis\/jix028","article-title":"Secretor and salivary ABO blood group antigen status predict rotavirus vaccine take in infants","volume":"215","author":"Kazi","year":"2017","journal-title":"Journal of Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"A129","DOI":"10.1016\/j.vaccine.2014.03.002","article-title":"Immunogenicity of a three dose and five dose oral human rotavirus vaccine (RIX4414) schedule in south Indian infants","volume":"32","author":"Kompithra","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.vaccine.2017.07.116","article-title":"The effect of probiotics and zinc supplementation on the immune response to oral rotavirus vaccine: a randomized, factorial design, placebo-controlled study among Indian infants","volume":"36","author":"Lazarus","year":"2018","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0319|cit319","unstructured":"Zinc and\/or probiotic supplementation of rotavirus and oral polio virus vaccines clinicaltrials.gov\/ct2\/show\/NCT01616693"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.vaccine.2017.11.031","article-title":"Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in south India","volume":"36","author":"Parker","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0321|cit321","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/cid\/ciy076","article-title":"Rotavirus-specific immunoglobulin A responses are impaired and serve as a suboptimal correlate of protection among infants in Bangladesh","volume":"67","author":"Lee","year":"2018","journal-title":"Clinical Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/INF.0000000000001253","article-title":"Rotavirus serum IgA immune response in children receiving rotarix coadministered with bOPV or IPV","volume":"35","author":"Ramani","year":"2016","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0323|cit323","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/vim.2006.0105","article-title":"Evaluation of circulating intestinally committed memory B cells in children vaccinated with attenuated human rotavirus vaccine","volume":"20","author":"Rojas","year":"2007","journal-title":"Viral Immunology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"A134","DOI":"10.1016\/j.vaccine.2014.04.078","article-title":"Effect of withholding breastfeeding on the immune response to a live oral rotavirus vaccine in North Indian infants","volume":"32","author":"Rongsen-Chandola","year":"2014","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/1745-6215-15-256","article-title":"Compliance of mothers following recommendations to breastfeed or withhold breast milk during rotavirus vaccination in North India: a randomized clinical trial","volume":"15","author":"Rongsen-Chandola","year":"2014","journal-title":"Trials"},{"issue":"25","key":"10.1002\/14651858.CD008521.pub6-BIB0326|cit326","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.vaccine.2015.04.057","article-title":"A randomized trial of rotavirus vaccine versus sucrose solution for vaccine injection pain","volume":"33","author":"Taddio","year":"2015","journal-title":"Vaccine"},{"issue":"7","key":"10.1002\/14651858.CD008521.pub6-BIB0327|cit327","doi-asserted-by":"publisher","first-page":"1147-51\u00a0","DOI":"10.1093\/infdis\/jiaa101","article-title":"Maternal secretor status affects oral rotavirus vaccine response in breastfed infants in Bangladesh","volume":"224","author":"Williams","year":"2021","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0328|cit328","unstructured":"Coadministration of measles-rubella and rotavirus vaccines clinicaltrials.gov\/ct2\/show\/NCT01700621"},{"issue":"11","key":"10.1002\/14651858.CD008521.pub6-BIB0329|cit329","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1093\/infdis\/jiw024","article-title":"Noninterference of rotavirus vaccine with measles-rubella vaccine at 9 months of age and improvements in antirotavirus immunity: a randomized trial","volume":"213","author":"Zaman","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"37","key":"10.1002\/14651858.CD008521.pub6-BIB0330|cit330","doi-asserted-by":"crossref","first-page":"5519","DOI":"10.1016\/j.vaccine.2018.07.064","article-title":"Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL (R) with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine","volume":"36","author":"Desai","year":"2018","journal-title":"Vaccine"},{"issue":"51","key":"10.1002\/14651858.CD008521.pub6-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.1016\/j.vaccine.2020.10.079","article-title":"A mixture model to assess the the immunogenicity of an oral rotavirus vaccine among healthy infants in Niger","volume":"38","author":"Hitchings","year":"2020","journal-title":"Vaccine"},{"issue":"19","key":"10.1002\/14651858.CD008521.pub6-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.vaccine.2019.03.067","article-title":"Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants","volume":"37","author":"Kawade","year":"2019","journal-title":"Vaccine"},{"issue":"52","key":"10.1002\/14651858.CD008521.pub6-BIB0333|cit333","doi-asserted-by":"crossref","first-page":"7943","DOI":"10.1016\/j.vaccine.2018.11.006","article-title":"A Phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants","volume":"36","author":"Rathi","year":"2018","journal-title":"Vaccine"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0334|cit334","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/INF.0b013e3181782780","article-title":"Concomitant use of the oral pentavalent human-bovine reassortant rotavirus vaccine and oral poliovirus vaccine","volume":"27","author":"Ciarlet","year":"2008","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/infdis\/jiy215","article-title":"Evaluation of a booster dose of pentavalent Rotavirus vaccine coadministered with measles, yellow fever, and meningitis A vaccines in 9-month-old Malian infants","volume":"218","author":"Haidara","year":"2018","journal-title":"Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/INF.0000000000002281","article-title":"Rotavirus vaccination does not increase type 1 diabetes and may decrease celiac disease in children and adolescents","volume":"38","author":"Hemming-Harlo","year":"2019","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0337|cit337","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/INF.0000000000001511","article-title":"Safety, tolerability and immunogenicity of pentavalent rotavirus vaccine manufactured by a modified process","volume":"36","author":"Martinon-Torres","year":"2017","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"13","key":"10.1002\/14651858.CD008521.pub6-BIB0338|cit338","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.vaccine.2019.02.018","article-title":"Immunogenicity of pentavalent rotavirus vaccine in Chinese infants","volume":"37","author":"Mo","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0339|cit339","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/jpids\/pix005","article-title":"Open-label pilot study to compare the safety and immunogenicity of pentavalent rotavirus vaccine (RV5) administered on an early alternative dosing schedule with those of RV5 administered on the recommended standard schedule","volume":"7","author":"Saleh","year":"2018","journal-title":"Journal of the Pediatric Infectious Diseases Society"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0340|cit340","unstructured":"A study to evaluate immune non-inferiority and safety of tetravalent Rotavirus vaccine (BRV-TV) in comparison to licensed vaccine (RotaTeq) in healthy infants ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=9950&EncHid=&userName=CTRI\/2014\/08\/004893"},{"issue":"28","key":"10.1002\/14651858.CD008521.pub6-BIB0341|cit341","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1016\/j.vaccine.2017.05.019","article-title":"Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): randomized, controlled phase III study in Indian infants","volume":"35","author":"Saluja","year":"2017","journal-title":"Vaccine"},{"issue":"Suppl","key":"10.1002\/14651858.CD008521.pub6-BIB0342|cit342","first-page":"S15-S61","article-title":"Clinical efficacy of rotavirus vaccine in Turkish infants","volume":"46","author":"Tugcu","year":"2009","journal-title":"Journal of Clinical Virology"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0343|cit343","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/infdis\/jix060","article-title":"Inflammation and immune activation in antiretroviral-treated human immunodeficiency virus type 1-infected African infants and rotavirus vaccine responses","volume":"215","author":"Uprety","year":"2017","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0344|cit344","unstructured":"An open-label, randomised, comparative, multi-centre study of the immunogenicity and safety of the concomitant use of a live pentavalent rotavirus vaccine (RotaTeq\u00ae) and a meningococcal Group C conjugate (MCC) vaccine in healthy infants clinicaltrials.gov\/ct2\/show\/record\/NCT00443846"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0345|cit345","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1128\/CVI.00437-10","article-title":"Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine","volume":"18","author":"Vesikari","year":"2011","journal-title":"Clinical Vaccine Immunology"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3389\/fimmu.2017.02002","article-title":"B and T cell phenotypic profiles of African HIV-infected and HIV-exposed uninfected infants: associations with antibody responses to the pentavalent rotavirus vaccine","volume":"8","author":"Weinberg","year":"2017","journal-title":"Frontiers in Immunology"},{"issue":"31","key":"10.1002\/14651858.CD008521.pub6-BIB0347|cit347","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1016\/j.vaccine.2019.05.069","article-title":"A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC\u00ae in comparison with a licensed rotavirus vaccine in healthy infants","volume":"37","author":"Ella","year":"2019","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"A122","DOI":"10.1016\/j.vaccine.2011.09.111","article-title":"Systematic review of regional and temporal trends in global rotavirus strain diversity in the prerotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs","volume":"30","author":"B\u00e1nyai","year":"2012","journal-title":"Vaccine"},{"issue":"9","key":"10.1002\/14651858.CD008521.pub6-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"e1036","DOI":"10.1016\/S2214-109X(18)30314-0","article-title":"Impact of monovalent rotavirus vaccine on diarrhoea-associated post-neonatal infant mortality in rural communities in Malawi: a population-based birth cohort study","volume":"6","author":"Bar-Zeev","year":"2018","journal-title":"Lancet Global Health"},{"issue":"9","key":"10.1002\/14651858.CD008521.pub6-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"e1195","DOI":"10.1016\/S2214-109X(20)30262-X","article-title":"Real-world effectiveness of rotavirus vaccines, 2006-19: a literature review and meta-analysis","volume":"8","author":"Burnett","year":"2020","journal-title":"Lancet Global Health"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/infdis\/jiaa081","article-title":"Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006-2019","volume":"222","author":"Burnett","year":"2020","journal-title":"Journal of Infectious Diseases"},{"issue":"16","key":"10.1002\/14651858.CD008521.pub6-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1016\/j.vaccine.2011.01.088","article-title":"Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia","volume":"29","author":"Buttery","year":"2011","journal-title":"Vaccine"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4161\/hv.26476","article-title":"The human rotavirus vaccine Rotarix\u2122 in infants: an integrated analysis of safety and reactogenicity","volume":"10","author":"Buyse","year":"2014","journal-title":"Human Vaccines and Immunotherapeutics"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0354|cit354","unstructured":"Calles NR Schutze GE Immunizations for children with HIV Module for HIV Curriculum available from: bipai.org\/sites\/bipai\/files\/20-Immunizations.pdf"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/cid\/cit520","article-title":"Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program","volume":"57","author":"Carlin","year":"2013","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0356|cit356","unstructured":"Advisory Committee on Immunization Practices Department of Health and Human Services Center for Disease Control and Prevention Summary Report, October 27-28, 2010 cdc.gov\/vaccines\/recs\/acip\/downloads\/min-archive\/min-oct10.pdf (URL no longer available)"},{"issue":"RR-2","key":"10.1002\/14651858.CD008521.pub6-BIB0357|cit357","first-page":"1","article-title":"Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"48","author":"Advisory Committee on Immunization Practices","year":"1999","journal-title":"MMWR. Recommendations and Reports"},{"issue":"7","key":"10.1002\/14651858.CD008521.pub6-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"P717","DOI":"10.1016\/S1473-3099(19)30126-4","article-title":"Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials","volume":"19","author":"Clark","year":"2019","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"17083","DOI":"10.1038\/nrdp.2017.83","article-title":"Rotavirus infection","volume":"3","author":"Crawford","year":"2017","journal-title":"Nature Reviews Disease Primers"},{"issue":"11","key":"10.1002\/14651858.CD008521.pub6-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/infdis\/jiw026","article-title":"Can changes to scheduling enhance the performance of rotavirus vaccines in low-income countries?","volume":"213","author":"Cunliffe","year":"2016","journal-title":"Journal of Infectious Diseases"},{"issue":"1671","key":"10.1002\/14651858.CD008521.pub6-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"pii: 20150142","DOI":"10.1098\/rstb.2015.0142","article-title":"Vaccines against enteric infections for the developing world","volume":"370","author":"Czerkinsky","year":"2015","journal-title":"Philosophical Transactions of the Royal Society of London"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.vaccine.2013.11.066","article-title":"Twenty-five years of the WHO vaccines prequalification programme (1987-2012): lessons learned and future perspectives","volume":"33","author":"Dellepiane","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/01.inf.0000164763.55558.71","article-title":"Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine","volume":"24","author":"Dennehy","year":"2005","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"e1001024","DOI":"10.1371\/journal.pmed.1001024","article-title":"Decline\u00a0in\u00a0diarrhea\u00a0mortality\u00a0and\u00a0admissions\u00a0after\u00a0routine\u00a0childhood\u00a0rotavirus\u00a0immunization\u00a0in Brazil: a\u00a0time-series\u00a0analysis","volume":"8","author":"Do Carmo","year":"2011","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0365|cit365","unstructured":"European Medicines Agency Summary of Product Characteristics: Rotarix ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000639\/WC500054789.pdf"},{"issue":"22","key":"10.1002\/14651858.CD008521.pub6-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1056\/NEJMc1107771","article-title":"Intussusception after rotavirus vaccination - spontaneous reports","volume":"365","author":"Escolano","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD008521.pub6-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.vaccine.2015.01.005","article-title":"Intussusception risk after RotaTeq vaccination: evaluation from worldwide spontaneous reporting data using a self-controlled case series approach","volume":"33","author":"Escolano","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD008521.pub6-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1186\/1471-2458-11-S3-S16","article-title":"Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect size","volume":"11","author":"Fischer Walker","year":"2011","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa1006261","article-title":"Protective effect of natural rotavirus infection in an Indian birth cohort","volume":"365","author":"Gladstone","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0370|cit370","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"8","key":"10.1002\/14651858.CD008521.pub6-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/cid\/ciz431","article-title":"Evaluation of intussusception after oral monovalent Rotavirus vaccination in South Africa","volume":"70","author":"Groome","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"7414","key":"10.1002\/14651858.CD008521.pub6-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency is preferable to testing for heterogeneity in meta-analysis","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0373|cit373","unstructured":"Higgins JP Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0374|cit374","unstructured":"Higgins JP Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1186\/s12879-017-2613-4","article-title":"Population effectiveness of the pentavalent and monovalent rotavirus vaccines: a systematic review and meta-analysis of observational studies","volume":"17","author":"Hungerford","year":"2017","journal-title":"BMC Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-017-0989-z","article-title":"Rotavirus vaccine impact and socioeconomic deprivation: an interrupted time-series analysis of gastrointestinal disease outcomes across primary and secondary care in the UK","volume":"16","author":"Hungerford","year":"2018","journal-title":"BMC Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/cid\/cix369","article-title":"Effectiveness of rotavirus vaccination: a systematic review of the first decade of global postlicensure data, 2006-2016","volume":"65","author":"Jonesteller","year":"2017","journal-title":"Clinical Infectious Diseases"},{"issue":"9","key":"10.1002\/14651858.CD008521.pub6-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/INF.0000000000001232","article-title":"A systematic review of the effect of rotavirus vaccination on diarrhea outcomes among children younger than 5 years","volume":"35","author":"Lamberti","year":"2016","journal-title":"Pediatric Infectious Disease Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1741-7007-8-129","article-title":"Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine","volume":"8","author":"Levine","year":"2010","journal-title":"BMC Biology"},{"issue":"9619","key":"10.1002\/14651858.CD008521.pub6-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0140-6736(08)60524-3","article-title":"Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study","volume":"371","author":"Linhares","year":"2008","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"e1912458","DOI":"10.1001\/jamanetworkopen.2019.12458","article-title":"Association between rotavirus vaccination and risk of intussusception among neonates and infants: a systematic review and meta-analysis","volume":"2","author":"Lu","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0382|cit382","unstructured":"WHO list of vaccines for purchase by UN agencies as of November 2008 www.who.int\/immunization_standards\/vaccine_quality\/pq_suppliers\/en\/index.html. Press release"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0383|cit383","unstructured":"Quality details for 9 RV5 included trials (correspondence) On file"},{"issue":"8","key":"10.1002\/14651858.CD008521.pub6-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJM200102223440804","article-title":"Intussusception among infants given an oral rotavirus vaccine","volume":"344","author":"Murphy","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"5775","key":"10.1002\/14651858.CD008521.pub6-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1126\/science.1128827","article-title":"Public health. Progress toward rotavirus vaccines","volume":"312","author":"Parashar","year":"2006","journal-title":"Science"},{"issue":"RR-12","key":"10.1002\/14651858.CD008521.pub6-BIB0386|cit386","first-page":"1","article-title":"Prevention of rotavirus gastroenteritis among infants and children. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"55","author":"Parashar","year":"2006","journal-title":"MMWR. Recommendations and Reports"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2217\/fmb-2017-0128","article-title":"Causes of impaired oral vaccine efficacy in developing countries","volume":"13","author":"Parker","year":"2018","journal-title":"Future Microbiology"},{"issue":"24","key":"10.1002\/14651858.CD008521.pub6-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa1012952","article-title":"Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil","volume":"364","author":"Patel","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"e1001330","DOI":"10.1371\/journal.pmed.1001330","article-title":"Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis","volume":"9","author":"Patel","year":"2012","journal-title":"PLOS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1097\/INF.0b013e31827d3b68","article-title":"Global seasonality of rotavirus disease","volume":"32","author":"Patel","year":"2013","journal-title":"Pediatric Infectious Diseases Journal"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0391|cit391","unstructured":"Country National Immunization Program (NIP) introductions of Rotavirus vaccine www.vaccineresources.org\/files\/PATH-Country-Introduction-Table-EN-2016.05.01.pdf"},{"issue":"Suppl","key":"10.1002\/14651858.CD008521.pub6-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jinf.2016.04.017","article-title":"Immunisation of the immunocompromised child","volume":"72","author":"Pinto","year":"2016","journal-title":"Journal of Infection"},{"issue":"505","key":"10.1002\/14651858.CD008521.pub6-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"eaav6419","DOI":"10.1126\/scitranslmed.aav6419","article-title":"Evaluating strategies to improve rotavirus vaccine impact during the second year of life in Malawi","volume":"11","author":"Pitzer","year":"2019","journal-title":"Science Translational Medicine"},{"issue":"20","key":"10.1002\/14651858.CD008521.pub6-BIB0394|cit394","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1056\/NEJMoa2002276","article-title":"Intussusception after rotavirus vaccine introduction in India","volume":"383","author":"Reddy","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0395|cit395","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0396|cit396","unstructured":"The Cochrane Collaboration Review Manager Web (RevMan Web)"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0397|cit397","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa0905211","article-title":"Effect of rotavirus vaccination on death from childhood diarrhea in Mexico","volume":"362","author":"Richardson","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0398|cit398","unstructured":"ROTA council Global introduction status preventrotavirus.org\/vaccine-introduction\/global-introduction-status\/"},{"issue":"3","key":"10.1002\/14651858.CD008521.pub6-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/00365549009027046","article-title":"Rotavirus disease in Finnish children: use of numerical scores for severity of diarrheal episodes","volume":"22","author":"Ruuska","year":"1990","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"23","key":"10.1002\/14651858.CD008521.pub6-BIB0400|cit400","first-page":"220","article-title":"Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations","volume":"84","year":"2009","journal-title":"Weekly Epidemiological Record"},{"issue":"87","key":"10.1002\/14651858.CD008521.pub6-BIB0401|cit401","first-page":"201","article-title":"Meeting of the immunization Strategic Advisory Group of Experts, April 2012 - conclusions and recommendations","volume":"21","year":"2012","journal-title":"Weekly Epidemiological Record"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0402|cit402","unstructured":"Sanderson C Clark A Taylor D Bolanos B Global review of rotavirus morbidity and mortality data by age and region www.who.int\/immunization\/sage\/meetings\/2012\/april\/Sanderson_et_al_SAGE_April_rotavirus.pdf"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0403|cit403","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JP Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jama.2012.97","article-title":"Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants","volume":"307","author":"Shui","year":"2012","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008521.pub6-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1086\/431512","article-title":"More on RotaShield and intussusception: the role of age at the time of vaccination","volume":"192","author":"Simonsen","year":"2005","journal-title":"Journal of Infectious Diseases"},{"issue":"4","key":"10.1002\/14651858.CD008521.pub6-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/21645515.2020.1804245","article-title":"Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1","volume":"17","author":"Skansberg","year":"2021","journal-title":"Human Vaccines & Immunotherapeutics"},{"issue":"32","key":"10.1002\/14651858.CD008521.pub6-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1016\/j.vaccine.2016.04.050","article-title":"The risk of intussusception following monovalent rotavirus vaccination in England: a self-controlled case-series evaluation","volume":"34","author":"Stowe","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0408|cit408","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1473-3099(11)70253-5","article-title":"2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis","volume":"12","author":"Tate","year":"2012","journal-title":"Lancet Infectious Diseases"},{"issue":"16","key":"10.1002\/14651858.CD008521.pub6-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1713909","article-title":"Evaluation of intussusception after monovalent rotavirus vaccination in Africa","volume":"378","author":"Tate","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0410|cit410","unstructured":"United Nations Inter-agency Group for Child Mortality Estimation (UN IGME) Levels & trends in child mortality: report 2019, estimates developed by the United Nations Inter-agency Group for child mortality estimation Available from unicef.org\/reports\/levels-and-trends-child-mortality-report-2019"},{"issue":"14","key":"10.1002\/14651858.CD008521.pub6-BIB0411|cit411","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJM199610033351404","article-title":"Rotavirus infection in infants as protection against subsequent infections","volume":"335","author":"Vel\u00e1zquez","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12887-016-0771-y","article-title":"Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean","volume":"17","author":"Vel\u00e1zquez","year":"2017","journal-title":"BMC Pediatrics"},{"issue":"9090","key":"10.1002\/14651858.CD008521.pub6-BIB0413|cit413","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/S0140-6736(97)03254-6","article-title":"Rotavirus vaccines against diarrhoeal disease","volume":"350","author":"Vesikari","year":"1997","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/INF.0000000000000683","article-title":"European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0415|cit415","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1311738","article-title":"Risk of intussusception after monovalent rotavirus vaccination","volume":"370","author":"Weintraub","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0416|cit416","unstructured":"World Health Organization Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization 5 -7 October 2020 www.who.int\/docs\/default-source\/mca-documents\/stage\/2-4-nov-2020-meeting\/stage-2-4-nov-2020-sage-oct-2020-meeting_short-summary_.pdf?sfvrsn=1ca0e652_5"},{"key":"10.1002\/14651858.CD008521.pub6-BIB0417|cit417","unstructured":"World Health Organization WHO prequalified vaccines extranet.who.int\/pqweb\/vaccines\/prequalified-vaccines"},{"issue":"28","key":"10.1002\/14651858.CD008521.pub6-BIB0418|cit418","first-page":"301","article-title":"Rotavirus vaccines WHO position paper - July 2021","volume":"96","author":"World Health Organization","year":"2021","journal-title":"Weekly Epidemiological Record"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.4161\/hv.28857","article-title":"Rotavirus vaccines: current status and future considerations","volume":"10","author":"Yen","year":"2014","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0420|cit420","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1080\/21645515.2016.1197452","article-title":"Rotavirus vaccination and intussusception - science, surveillance, and safety: a review of evidence and recommendations for future research priorities in low and middle income countries","volume":"12","author":"Yen","year":"2016","journal-title":"Human Vaccines and Immunotherapeutics"},{"issue":"6","key":"10.1002\/14651858.CD008521.pub6-BIB0421|cit421","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1303164","article-title":"Intussusception risk after rotavirus vaccination in U.S. infants","volume":"370","author":"Yih","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008521.pub6-BIB0422|cit422","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002848.pub2","article-title":"Rotavirus vaccine for preventing diarrhoea","author":"Soares-Weiser","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD008521.pub6-BIB0423|cit423","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008521","article-title":"Vaccines for preventing rotavirus diarrhoea: vaccines in use","author":"Soares-Weiser","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008521.pub6-BIB0424|cit424","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008521.pub2","article-title":"Vaccines\u00a0for preventing\u00a0rotavirus\u00a0diarrhoea:\u00a0vaccines\u00a0in use","author":"\u00a0MacLehose","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD008521.pub6-BIB0425|cit425","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008521.pub3","article-title":"Vaccines for preventing rotavirus diarrhoea: vaccines in use","author":"Soares-Weiser","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD008521.pub6-BIB0426|cit426","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008521.pub4","article-title":"Vaccines for preventing\u00a0rotavirus\u00a0diarrhoea: vaccines in use","author":"Soares-Weiser","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T20:11:04Z","timestamp":1699819864000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008521.pub6"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":426,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008521.pub6","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]}}}